Medical Management for Hematoma, Subdural, Chronic
Phase-Based Progress Estimates
Effectiveness
Safety
Hematoma, Subdural, Chronic+2 More
Medical Management - OtherEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is designed to see if a new treatment for chronic subdural hematoma (a buildup of blood on the brain) is safe and effective.
Eligible Conditions
- Hematoma, Subdural, Chronic
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: within 180-days of intervention
within 180-days of intervention
Treatment failure
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
No Embolization
1 of 2
Embolization
1 of 2
Active Control
Experimental Treatment
310 Total Participants · 2 Treatment Groups
Primary Treatment: Medical Management · No Placebo Group · N/A
EmbolizationExperimental Group · 3 Interventions: Medical Management, Burr-hole, SQUID · Intervention Types: Other, Procedure, Device
No EmbolizationActiveComparator Group · 2 Interventions: Medical Management, Burr-hole · Intervention Types: Other, Procedure
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 180-days of intervention
Who is running the clinical trial?
AXIOM Real Time MetricsUNKNOWN
2 Previous Clinical Trials
275 Total Patients Enrolled
Embo-Flüssigkeiten A.G.Industry Sponsor
1 Previous Clinical Trials
111 Total Patients Enrolled
Balt ExtrusionIndustry Sponsor
5 Previous Clinical Trials
10,710 Total Patients Enrolled
Balt USALead Sponsor
David Fiorella, MD, PhDPrincipal InvestigatorStony Brook University Medical Center
2 Previous Clinical Trials
1,013 Total Patients Enrolled
Adam Arthur, MD, MPHPrincipal InvestigatorSemmes-Murphy Neurologic and Spine Institute
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are male or female and your age is 30 or older.
You have no symptoms of stroke in the past 12 months.
The subjacent brain is flattened or shifted.
Imaging characteristics indicative of chronicity (≥ 50% of the volume of the collection should be isodense or hypodense to normal cortical gray matter on CT).
You are female and of child-bearing potential
You are willing and able to return to the investigational site for all follow-up visits (e.g., 30-day, 90-day, 180-day and 1-year), as required per protocol.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments